Return Of The Me-Too? Big Pharma's 2016 Approval Prospects Stick To Familiar Categories
Executive Summary
Few pending novel agents from big pharma are first-in-class, as firms look to build their portfolios in crowded areas that still have big sales potential – especially in immunology and immuno-oncology.